Chimeric Antigen Receptor (CAR) T-Cell Therapy.
Explore this paper's citation graph
Summary
Since their initial development in the 1990s, CAR T cells have evolved through several generations, with researchers fine-tuning the safety and efficacy profiles using novel concepts and technologies.
- Type
- article
- Published
- 2017-11-01
- Cited by
- 45
- References
- 29
- OpenAlex
- https://openalex.org/W2751887482
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:56477933
Keywords
Chimeric antigen receptor, Medicine, CAR T-cell therapy, Antigen, Immunotherapy
References
- Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy.
- Chimeric antigen receptor T cells for cancer immunotherapy.
- The past and future of CD33 as therapeutic target in acute myeloid leukemia.
- The basic principles of chimeric antigen receptor (CAR) design
- Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects
- Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
- Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
- Toxicity and management in CAR T-cell therapy
- CAR T Cell Therapy: A Game Changer in Cancer Treatment
- Chimeric antigen receptor (CAR) T cell therapy for malignant cancers: Summary and perspective
- The growing world of CAR T cell trials: a systematic review
- Safety concerns blight promising cancer therapy
- The Promise of Chimeric Antigen Receptor T-Cell Therapy.
- Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy
- Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
- CAR T‐Cell Therapy: Update on the state of the science
- CAR T Cell Toxicity: Current Management and Future Directions
- Managing the toxicities of CAR T‐cell therapy
- Medicare to Cover CAR T-Cell Therapies.
- Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial
Cited by
- Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer
- Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment.
- Comparative analysis and optimization of protocols for producing recombinant lentivirus carrying the anti‐Her2 chimeric antigen receptor gene
- Economic burden associated with adverse events of special interest in patients with relapsed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in the United States
- Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy
- Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
- Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy
- Chimeric Antigen Receptor T-Cell Therapy: A Beacon of Hope in the Fight Against Cancer
- What is the future of cancer care? A technology foresight assessment of experts’ expectations
- Role of the actin cytoskeleton in breast cancer cell resistance to natural killer cells
- Chimeric Antigen Receptor T-Cell Therapy: What the Neuroradiologist Needs to Know
- Immunoregulatory Potential of Exosomes Derived from Cancer Stem Cells
- Development of oncolytic virotherapy: from genetic modification to combination therapy
- The COVID-19 Pandemic and its Impact on the Cardio-Oncology Population
- Chimeric Antigen Receptor (CAR) T-Cell Therapy: Case Histories of Significant Medical Advances
- Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma
- Emerging Paradigm-Shifting in Cancer Immunotherapeutic Towards Personalized Cancer Medicine and Potential Challenges
- In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B‐Cell Lymphoma
- Chimeric antigen receptor T cell structure, its manufacturing, and related toxicities; A comprehensive review
- Rehabilitation Needs for Patients Undergoing CAR T-Cell Therapy
Related papers
- Advantages and Disadvantages of Car-T Therapy in the Clinical Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)
- Current status and problems of chimeric antigen receptor T cell immunotherapy in treatment of hematological malignancies
- The present situation and prospect of CAR-T cellular immunotherapy
- Limitations and Overcomes of CAR-NK for Cancer Immunotherapy
- Role of bridging therapy during chimeric antigen receptor T cell therapy
- CAR-T Immunotherapy to Beat Solid Tumors: From Challenges to Improvements
- Utilization of CAR T Cell Therapy in Pediatric Patients.
- A computational approach to the description of individual immune responses
- Innovations in cancer immunotherapy: chimeric antigen receptor T-cell therapy (CAR-T)
- Chimeric antigen receptor T cell therapy and other therapeutics for malignancies: Combination and opportunity.